125 related articles for article (PubMed ID: 20106510)
41. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
42. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
43. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
44. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.
Pollock PM; Gartside MG; Dejeza LC; Powell MA; Mallon MA; Davies H; Mohammadi M; Futreal PA; Stratton MR; Trent JM; Goodfellow PJ
Oncogene; 2007 Nov; 26(50):7158-62. PubMed ID: 17525745
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*.
Tanyi J; Tory K; Rigó J; Nagy B; Papp Z
Pathol Oncol Res; 1999; 5(3):187-91. PubMed ID: 10491015
[TBL] [Abstract][Full Text] [Related]
46. Histotype-specific copy-number alterations in ovarian cancer.
Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
[TBL] [Abstract][Full Text] [Related]
47. Rapid Identification of FGFR2 Gene Mutations in Taiwanese Patients With Endometrial Cancer Using High-resolution Melting Analysis.
Lin YC; Er TK; Yeh KT; Hung CH; Chang JG
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):532-7. PubMed ID: 25517871
[TBL] [Abstract][Full Text] [Related]
48. FGFR2 as a molecular target in endometrial cancer.
Byron SA; Pollock PM
Future Oncol; 2009 Feb; 5(1):27-32. PubMed ID: 19243295
[TBL] [Abstract][Full Text] [Related]
49. Ovarian dysgerminoma and Apert syndrome.
Rouzier C; Soler C; Hofman P; Brennetot C; Bieth E; Pedeutour F
Pediatr Blood Cancer; 2008 Mar; 50(3):696-8. PubMed ID: 17243131
[TBL] [Abstract][Full Text] [Related]
50. Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.
Spiegelberg C; Giedl J; Gaisa NT; Rogler A; Riener MO; Filbeck T; Burger M; Ruemmele P; Hartmann A; Stoehr R
Int J Clin Exp Pathol; 2014; 7(4):1708-13. PubMed ID: 24817968
[TBL] [Abstract][Full Text] [Related]
51. Chromosome abnormalities in primary endometrioid ovarian carcinoma.
Yonescu R; Currie JL; Hedrick L; Campbell J; Griffin CA
Cancer Genet Cytogenet; 1996 Apr; 87(2):167-71. PubMed ID: 8625265
[TBL] [Abstract][Full Text] [Related]
52. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Wang F; Zou Y; Liu FY; Yu XH; Huang H; Zhang N; Qi YY; Liu RF; Liu XY; Chen J; Huang OP; He M
Mol Med Rep; 2013 Jun; 7(6):1826-30. PubMed ID: 23588898
[TBL] [Abstract][Full Text] [Related]
53. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
Kim DH; Kwak Y; Kim ND; Sim T
Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
[TBL] [Abstract][Full Text] [Related]
54. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
Shih IeM; Panuganti PK; Kuo KT; Mao TL; Kuhn E; Jones S; Velculescu VE; Kurman RJ; Wang TL
Am J Pathol; 2011 Apr; 178(4):1442-7. PubMed ID: 21435433
[TBL] [Abstract][Full Text] [Related]
55. FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.
Stehbens SJ; Ju RJ; Adams MN; Perry SR; Haass NK; Bryant DM; Pollock PM
J Cell Sci; 2018 Aug; 131(15):. PubMed ID: 30002137
[TBL] [Abstract][Full Text] [Related]
56. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Tanizaki J; Ercan D; Capelletti M; Dodge M; Xu C; Bahcall M; Tricker EM; Butaney M; Calles A; Sholl LM; Hammerman PS; Oxnard GR; Wong KK; Jänne PA
Cancer Res; 2015 Aug; 75(15):3139-46. PubMed ID: 26048680
[TBL] [Abstract][Full Text] [Related]
57. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
Lei H; Deng CX
Int J Biol Sci; 2017; 13(9):1163-1171. PubMed ID: 29104507
[TBL] [Abstract][Full Text] [Related]
58. Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Dutt A; Salvesen HB; Chen TH; Ramos AH; Onofrio RC; Hatton C; Nicoletti R; Winckler W; Grewal R; Hanna M; Wyhs N; Ziaugra L; Richter DJ; Trovik J; Engelsen IB; Stefansson IM; Fennell T; Cibulskis K; Zody MC; Akslen LA; Gabriel S; Wong KK; Sellers WR; Meyerson M; Greulich H
Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8713-7. PubMed ID: 18552176
[TBL] [Abstract][Full Text] [Related]
59. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.
Dixit G; Gonzalez-Bosquet J; Skurski J; Devor EJ; Dickerson EB; Nothnick WB; Issuree PD; Leslie KK; Maretzky T
Clin Transl Med; 2023 May; 13(5):e1223. PubMed ID: 37165578
[TBL] [Abstract][Full Text] [Related]
60. Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
Dixit G; Pappas BA; Bhardwaj G; Schanz W; Maretzky T
Cells; 2023 Sep; 12(18):. PubMed ID: 37759450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
